

# Provention Bio To Present at 8th Annual Leerink Partners Global Healthcare Conference

OLDWICK, N.J., Feb. 13, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics aimed at intercepting and preventing immune-mediated diseases, announced today its Chief Executive Officer, Ashleigh Palmer, along with other members of Provention's executive management team, will participate in a fireside chat presentation at the 8<sup>th</sup> Annual Leerink Partners Global Healthcare Conference being held February 27-March 1, 2019, at the Lotte New York Palace in New York City.

Details of Provention's presentation are as follows:

**Conference:** 8<sup>th</sup> Annual Leerink Partners Global Healthcare Conference  
**Date:** Wednesday, February 27, 2019  
**Time:** 11:00 am (ET)  
**Location:** Lotte New York Palace, New York; Track 6 - Louis, 4<sup>th</sup> Floor

An audio webcast will be accessible via the Events and Webcasts section of the Provention Bio website: <http://investors.proventionbio.com/events>. An archive of the audio will remain available for 90 days following the presentation.

## About Provention Bio, Inc.

Provention Bio, Inc. (Nasdaq: PRVB) is a clinical-stage biopharmaceutical company leveraging a transformational drug development strategy that is focused on the prevention or interception of immune-mediated disease. Provention's mission is to in-license, transform and develop therapeutic candidates targeting the high morbidity, mortality and escalating costs of autoimmune and inflammatory diseases including: type 1 diabetes (T1D), Crohn's disease, ulcerative colitis, celiac disease, lupus, and certain life-threatening viral diseases. Provention's diversified portfolio includes advanced-stage product development candidates that have undergone clinical testing by other companies. For more information on Provention Bio, please visit [www.proventionbio.com](http://www.proventionbio.com).

## Forward Looking Statements

*Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," and "intend," among others. These forward-looking statements are based on Provention's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to failure to obtain FDA approvals or clearances and noncompliance with FDA regulations; uncertainties of patent protection and litigation; limited research and development efforts and dependence upon third parties; substantial competition; our need for additional financing and the risks listed under "Risk factors" in our quarterly report on Form 10-Q for the quarter ended September 30, 2018 and any subsequent filings with the Securities and Exchange Commission (SEC). As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Provention does not undertake an obligation to update or revise any forward-looking statement. The information set forth herein speaks only as of the date hereof.*

## Media & Investor Contacts

Jason Rando / Joshua Drumm, Ph.D.

[Tiberend Strategic Advisors, Inc.](http://www.tiberend.com)

T: 212 375 2665 / 212 375 2664

[jrando@tiberend.com](mailto:jrando@tiberend.com)

[jdrumm@tiberend.com](mailto:jdrumm@tiberend.com)

SOURCE Provention Bio, Inc.